[{"address1": "4000 Shoreline Court", "address2": "Suite 300", "city": "South San Francisco", "state": "CA", "zip": "94080", "country": "United States", "phone": "650 822 5600", "website": "https://www.kezarlifesciences.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.", "fullTimeEmployees": 58, "companyOfficers": [{"maxAge": 1, "name": "Dr. Christopher J. Kirk Ph.D.", "age": 52, "title": "Co-Founder, CEO & Director", "yearBorn": 1972, "fiscalYear": 2023, "totalPay": 644685, "exercisedValue": 0, "unexercisedValue": 5485}, {"maxAge": 1, "name": "Mr. John Franklin Fowler", "age": 52, "title": "Co-Founder & Director", "yearBorn": 1972, "fiscalYear": 2023, "totalPay": 539349, "exercisedValue": 0, "unexercisedValue": 2641}, {"maxAge": 1, "name": "Mr. Marc L. Belsky CPA", "age": 69, "title": "CFO & Secretary", "yearBorn": 1955, "fiscalYear": 2023, "totalPay": 639413, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Jack  Taunton Ph.D.", "title": "Co-Founder", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Gitanjali  Jain", "title": "Senior Vice President of Investor Relations & External Affairs", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Mark  Schiller", "age": 44, "title": "Chief Legal Officer", "yearBorn": 1980, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Joe  Tedrick", "title": "Vice President of Human Resources", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Neel K. Anand Ph.D.", "title": "Senior Vice President of Research & Drug Discovery", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Zung  To", "title": "Senior Vice President of Clinical Development", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Pattie  Chiang", "title": "Senior VP & Corporate Controller", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 7, "boardRisk": 7, "compensationRisk": 10, "shareHolderRightsRisk": 9, "overallRisk": 10, "governanceEpochDate": 1738368000, "compensationAsOfEpochDate": 1703980800, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 6.4, "open": 6.4, "dayLow": 6.14, "dayHigh": 6.4, "regularMarketPreviousClose": 6.4, "regularMarketOpen": 6.4, "regularMarketDayLow": 6.14, "regularMarketDayHigh": 6.4, "payoutRatio": 0.0, "beta": 0.186, "forwardPE": -0.5893028, "volume": 5611, "regularMarketVolume": 5611, "averageVolume": 42949, "averageVolume10days": 31900, "averageDailyVolume10Day": 31900, "bid": 4.58, "ask": 7.85, "bidSize": 2, "askSize": 2, "marketCap": 45017676, "fiftyTwoWeekLow": 5.2, "fiftyTwoWeekHigh": 11.4, "priceToSalesTrailing12Months": "Infinity", "fiftyDayAverage": 6.4434, "twoHundredDayAverage": 6.76, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": -84780176, "profitMargins": 0.0, "floatShares": 4552988, "sharesOutstanding": 7296220, "sharesShort": 77734, "sharesShortPriorMonth": 85333, "sharesShortPreviousMonthDate": 1735603200, "dateShortInterest": 1738281600, "sharesPercentSharesOut": 0.0107, "heldPercentInsiders": 0.11996, "heldPercentInstitutions": 0.5762, "shortRatio": 2.25, "shortPercentOfFloat": 0.0109, "impliedSharesOutstanding": 7296220, "bookValue": 18.372, "priceToBook": 0.33583716, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -95778000, "trailingEps": -13.12, "forwardEps": -10.47, "lastSplitFactor": "1:10", "lastSplitDate": 1730246400, "enterpriseToEbitda": 0.893, "52WeekChange": -0.28888887, "SandP52WeekChange": 0.2021538, "quoteType": "EQUITY", "currentPrice": 6.17, "targetHighPrice": 18.0, "targetLowPrice": 9.0, "targetMeanPrice": 13.5, "targetMedianPrice": 13.5, "recommendationMean": 2.33333, "recommendationKey": "buy", "numberOfAnalystOpinions": 2, "totalCash": 148388000, "totalCashPerShare": 20.338, "ebitda": -94901000, "totalDebt": 16912000, "quickRatio": 7.317, "currentRatio": 7.655, "totalRevenue": 0, "debtToEquity": 12.616, "revenuePerShare": 0.0, "returnOnAssets": -0.29015, "returnOnEquity": -0.54724, "grossProfits": -72354000, "freeCashflow": -43092124, "operatingCashflow": -76367000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "KZR", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "shortName": "Kezar Life Sciences, Inc.", "longName": "Kezar Life Sciences, Inc.", "fiftyTwoWeekHighChangePercent": -0.4587719, "fiftyTwoWeekChangePercent": -28.888887, "earningsTimestampStart": 1741777140, "earningsTimestampEnd": 1742212800, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -13.12, "epsForward": -10.47, "epsCurrentYear": -6.7, "priceEpsCurrentYear": -0.9208956, "fiftyDayAverageChange": -0.27339983, "fiftyDayAverageChangePercent": -0.04243099, "twoHundredDayAverageChange": -0.59000015, "twoHundredDayAverageChangePercent": -0.08727813, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "2.3 - Buy", "cryptoTradeable": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1529587800000, "regularMarketChange": -0.23000002, "regularMarketDayRange": "6.14 - 6.4", "fullExchangeName": "NasdaqCM", "averageDailyVolume3Month": 42949, "fiftyTwoWeekLowChange": 0.97000027, "fiftyTwoWeekLowChangePercent": 0.18653852, "fiftyTwoWeekRange": "5.2 - 11.4", "fiftyTwoWeekHighChange": -5.2299995, "corporateActions": [], "regularMarketTime": 1740168727, "exchange": "NCM", "messageBoardId": "finmb_304157325", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": -3.5937502, "regularMarketPrice": 6.17, "marketState": "REGULAR", "displayName": "Kezar Life Sciences", "trailingPegRatio": null, "__fetch_time": "2025-02-21"}]